AccuMetab™ Human CYP2E1 Enzyme, Catalytically Active

CAT#: ITS-0426-YL16
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2E1 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP2E1 specializes in the metabolism of low-molecular-weight xenobiotics, including ethanol, acetaminophen, and volatile organic solvents. It is highly prone to generating reactive oxygen species, making it an indispensable enzyme for evaluating drug-induced hepatotoxicity and the formation of toxic metabolic intermediates.
Key Features
Proprietary E. coli expression; Validated for low molecular weight xenobiotics; Critical for acetaminophen and ethanol clearance; Primary model for ROS-induced hepatotoxicity
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Toxicology; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry